Pregabalin
Product Images NDC 45865-107

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 45865-107). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medsource Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pregabalin Capsules 75 mg (Pdp 107)

Packaging label for Pregabalin capsules 75 mg, generic for Lyrica, manufactured by ScieGen Pharmaceuticals Inc. The label indicates a quantity of 30 capsules, with each capsule containing 75 mg of pregabalin. It includes directions to take as directed by a physician and a federal warning against drug transfer to others. The lot number and expiration date fields are present but not specified.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph depicting percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin dosages of 200 mg, 100 mg, 25 mg taken three times a day, and placebo. The graph shows four lines representing these groups with percent improvement on the horizontal axis and percent of patients improved on the vertical axis.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph comparing percent of patients improved against percent improvement in pain from baseline, showing two lines representing Pregabalin 100 mg three times a day and placebo. The vertical axis indicates percent of patients improved, ranging from 0 to 100, and the horizontal axis shows percent improvement in pain from baseline, ranging from greater than 0 to 100.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph illustrating the percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin at 75 mg, 150 mg, and 300 mg doses taken twice a day, alongside a placebo. The x-axis represents percent improvement in pain from baseline, and the y-axis shows the percentage of patients improved.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo groups. The vertical axis shows percent of patients improved, ranging from 0 to 100, and the horizontal axis shows percent improvement in pain from baseline, ranging from 0 to 100.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph showing percent of patients improved versus percent improvement in pain from baseline for Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo groups. The graph compares pain improvement outcomes among these treatment groups.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar chart comparing responder rates (%) across different dosing groups in two clinical studies labeled Study E1 and Study E3, including placebo and various daily doses. The chart shows statistically significant increases in responder rates at higher doses compared to placebo, with respective sample sizes indicated below each bar.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A dose-response line graph depicting seizure reduction as median percentage change from baseline versus dose (mg/day) for Pregabalin. It includes four study groups labeled Study E1 BD, Study E2 TID, Study E3 BD, and Study E3 TID, with p-values indicating statistical significance. The x-axis is dose in mg/day, and the y-axis is median seizure reduction. Placebo dose is marked at zero.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph depicting the percent of patients improved on the vertical axis against percent improvement in pain from baseline on the horizontal axis, comparing four groups: Pregabalin 800mg, 450mg, 300mg daily doses, and placebo. The graph shows a trend of higher improvement percentages with increasing pregabalin doses compared to placebo.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A survival curve chart comparing Pregabalin and placebo over 180 days, showing the estimated percentage of subjects without LTR (last treatment response). The y-axis represents the estimated percentage of subjects without LTR from 0% to 100%, and the x-axis represents days from 0 to 180. The solid line represents Pregabalin, while the dashed line represents placebo, indicating higher retention without LTR for Pregabalin over time.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing the percent of subjects improved over time from baseline to week 12 for Pregabalin versus Placebo. The x-axis shows percent improved from baseline to week 12 BOCF, and the y-axis shows the percent of subjects improved. Solid line represents Pregabalin, and the dashed line represents Placebo, indicating higher improvement percentages for Pregabalin throughout the range.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line chart comparing the percentage of subjects improved from baseline to week 16 using the BOCF method for Pregabalin and placebo groups. The x-axis shows percent improvement, and the y-axis shows the percent of subjects improved. Pregabalin shows higher improvement percentages compared to placebo across the range.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A formula for calculating creatinine clearance (CLcr) is shown, involving age in years, weight in kilograms, serum creatinine in mg/dL, and a multiplier of 0.85 for female patients. The equation is used to estimate kidney function.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of pregabalin showing its molecular arrangement with an amino group, carboxylic acid, and a branched hydrocarbon chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.